Gland Pharma's Rs 6,480-crore IPO gets 4% subscription on first day
On Friday, the company had allotted Rs 1,944 crore worth of shares to anchor investors
 "Gland Pharma's Rs 6,480-crore IPO gets 4% subscription on first day")
premium
Hyderabad-based Gland Pharma’s initial public offering (IPO) was subscribed 4 per cent on Monday, the first day of the issue. The offering has received bids for 1.1 million shares as against 30 million on offer.
On Friday, the company had allotted Rs 1,944 crore worth of shares to anchor investors.
China’s Fosun Pharma-promoted firm is looking to raise Rs 1,250 crore through the IPO by issuing new shares.
The IPO also comprises of secondary share sale worth Rs 5,230 crore. The total IPO size is about Rs 6,480-crore, making it one of the biggest pharma IPO in the domestic market.
The price band has been set at Rs 1,490-1,500 per share. At the top-end, Gland will have a market cap of around Rs 24,500 crore.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%